Literature DB >> 26116406

Chemopreventive Effects of Korean Angelica versus Its Major Pyranocoumarins on Two Lineages of Transgenic Adenocarcinoma of Mouse Prostate Carcinogenesis.

Su-Ni Tang1, Jinhui Zhang1, Wei Wu1, Peixin Jiang1, Manohar Puppala2, Yong Zhang1, Chengguo Xing2, Sung-Hoon Kim3, Cheng Jiang1, Junxuan Lü4.   

Abstract

We showed previously that daily gavage of Angelica gigas Nakai (AGN) root ethanolic extract starting 8 weeks of age inhibited growth of prostate epithelium and neuroendocrine carcinomas (NE-Ca) in the transgenic adenocarcinoma of mouse prostate (TRAMP) model. Because decursin (D) and its isomer decursinol angelate (DA) are major pyranocoumarins in AGN extract, we tested the hypothesis that D/DA represented active/prodrug compounds against TRAMP carcinogenesis. Three groups of male C57BL/6 TRAMP mice were gavage treated daily with excipient vehicle, AGN (5 mg per mouse), or equimolar D/DA (3 mg per mouse) from 8 weeks to 16 or 28 weeks of age. Measurement of plasma and NE-Ca D, DA, and their common metabolite decursinol indicated similar retention from AGN versus D/DA dosing. The growth of TRAMP dorsolateral prostate (DLP) in AGN- and D/DA-treated mice was inhibited by 66% and 61% at 16 weeks and by 67% and 72% at 28 weeks, respectively. Survival of mice bearing NE-Ca to 28 weeks was improved by AGN, but not by D/DA. Nevertheless, AGN- and D/DA-treated mice had lower NE-Ca burden. Immunohistochemical and mRNA analyses of DLP showed that AGN and D/DA exerted similar inhibition of TRAMP epithelial lesion progression and key cell-cycle genes. Profiling of NE-Ca mRNA showed a greater scope of modulating angiogenesis, epithelial-mesenchymal transition, invasion-metastasis, and inflammation genes by AGN than D/DA. The data therefore support D/DA as probable active/prodrug compounds against TRAMP epithelial lesions, and they cooperate with non-pyranocoumarin compounds to fully express AGN efficacy against NE-Ca. ©2015 American Association for Cancer Research.

Entities:  

Mesh:

Substances:

Year:  2015        PMID: 26116406      PMCID: PMC4648373          DOI: 10.1158/1940-6207.CAPR-15-0051

Source DB:  PubMed          Journal:  Cancer Prev Res (Phila)        ISSN: 1940-6215


  37 in total

1.  In vitro metabolism of pyranocoumarin isomers decursin and decursinol angelate by liver microsomes from man and rodents.

Authors:  Li Li; Jinhui Zhang; Chengguo Xing; Sung-Hoon Kim; Cheng Jiang; Junxuan Lü
Journal:  Planta Med       Date:  2013-09-11       Impact factor: 3.352

2.  Quantitative determination of decursin, decursinol angelate, and decursinol in mouse plasma and tumor tissue using liquid-liquid extraction and HPLC.

Authors:  Li Li; Jinhui Zhang; Ahmad Ali Shaik; Yong Zhang; Lei Wang; Chengguo Xing; Sung-Hoon Kim; Junxuan Lü
Journal:  Planta Med       Date:  2011-11-24       Impact factor: 3.352

3.  Mouse prostate proteome changes induced by oral pentagalloylglucose treatment suggest targets for cancer chemoprevention.

Authors:  J Zhang; K Nkhata; A A Shaik; L Wang; L Li; Y Zhang; L A Higgins; K H Kim; J D Liao; C Xing; S-H Kim; J Lu
Journal:  Curr Cancer Drug Targets       Date:  2011-09       Impact factor: 3.428

4.  Plumbagin inhibits prostate cancer development in TRAMP mice via targeting PKCε, Stat3 and neuroendocrine markers.

Authors:  Bilal Bin Hafeez; Weixiong Zhong; Ala Mustafa; Joseph W Fischer; Olya Witkowsky; Ajit K Verma
Journal:  Carcinogenesis       Date:  2012-09-13       Impact factor: 4.944

5.  A grading scheme for the assessment of proliferative lesions of the mouse prostate in the TRAMP model.

Authors:  Andrew Suttie; Abraham Nyska; Joseph K Haseman; Glenda J Moser; Theleria R Hackett; Thomas L Goldsworthy
Journal:  Toxicol Pathol       Date:  2003 Jan-Feb       Impact factor: 1.902

Review 6.  Flap endonuclease 1.

Authors:  Lata Balakrishnan; Robert A Bambara
Journal:  Annu Rev Biochem       Date:  2013-02-28       Impact factor: 23.643

7.  Single oral dose pharmacokinetics of decursin, decursinol angelate, and decursinol in rats.

Authors:  Li Li; Jinhui Zhang; Chengguo Xing; Sung-Hoon Kim; Junxuan Lü
Journal:  Planta Med       Date:  2013-01-30       Impact factor: 3.352

Review 8.  Anti-cancer and other bioactivities of Korean Angelica gigas Nakai (AGN) and its major pyranocoumarin compounds.

Authors:  Jinhui Zhang; Li Li; Cheng Jiang; Chengguo Xing; Sung-Hoon Kim; Junxuan Lü
Journal:  Anticancer Agents Med Chem       Date:  2012-12       Impact factor: 2.505

9.  First-pass metabolism of decursin, a bioactive compound of Angelica gigas, in rats.

Authors:  Hyun Seo Park; Byunghyun Kim; Ju-Hee Oh; Young Choong Kim; Young-Joo Lee
Journal:  Planta Med       Date:  2012-05-09       Impact factor: 3.352

10.  Single oral dose pharmacokinetics of decursin and decursinol angelate in healthy adult men and women.

Authors:  Jinhui Zhang; Li Li; Thomas W Hale; Wayne Chee; Chengguo Xing; Cheng Jiang; Junxuan Lü
Journal:  PLoS One       Date:  2015-02-19       Impact factor: 3.240

View more
  6 in total

1.  Pyranocoumarin Tissue Distribution, Plasma Metabolome and Prostate Transcriptome Impacts of Sub-Chronic Exposure to Korean Angelica Supplement in Mice.

Authors:  Jinhui Zhang; Li Li; Suni Tang; Yong Zhang; Maciej Markiewski; Chengguo Xing; Cheng Jiang; Junxuan Lü
Journal:  Am J Chin Med       Date:  2016       Impact factor: 4.667

2.  Prostate Cancer Xenograft Inhibitory Activity and Pharmacokinetics of Decursinol, a Metabolite of Angelica gigas Pyranocoumarins, in Mouse Models.

Authors:  Wei Wu; Su-Ni Tang; Yong Zhang; Manohar Puppala; Timothy K Cooper; Chengguo Xing; Cheng Jiang; Junxuan Lü
Journal:  Am J Chin Med       Date:  2017-11-09       Impact factor: 4.667

3.  Interception Targets of Angelica Gigas Nakai Root Extract versus Pyranocoumarins in Prostate Early Lesions and Neuroendocrine Carcinomas in TRAMP Mice.

Authors:  Su-Ni Tang; Peixin Jiang; Sangyub Kim; Jinhui Zhang; Cheng Jiang; Junxuan Lü
Journal:  Cancer Prev Res (Phila)       Date:  2021-03-01

Review 4.  Dietary Compounds for Targeting Prostate Cancer.

Authors:  Seungjin Noh; Eunseok Choi; Cho-Hyun Hwang; Ji Hoon Jung; Sung-Hoon Kim; Bonglee Kim
Journal:  Nutrients       Date:  2019-10-08       Impact factor: 5.717

5.  Flavokawain A induces deNEDDylation and Skp2 degradation leading to inhibition of tumorigenesis and cancer progression in the TRAMP transgenic mouse model.

Authors:  Xuesen Li; Noriko N Yokoyama; Saiyang Zhang; Lina Ding; Hong-min Liu; Michael B Lilly; Dan Mercola; Xiaolin Zi
Journal:  Oncotarget       Date:  2015-12-08

Review 6.  Structure-Based Classification and Anti-Cancer Effects of Plant Metabolites.

Authors:  Seong-Ah Shin; Sun Young Moon; Woe-Yeon Kim; Seung-Mann Paek; Hyun Ho Park; Chang Sup Lee
Journal:  Int J Mol Sci       Date:  2018-09-06       Impact factor: 5.923

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.